Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069712 · ClinicalTrials.gov registry record · Phase 2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
A Phase 2 study of Gastroesophageal Adenocarcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07069712 is a Phase 2 study of Gastroesophageal Adenocarcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 100 participants, below the 138-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT07069712, a Phase 2 study of Gastroesophageal Adenocarcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG 5-Fluorouracil (5-FU)
- DRUG Rilvegostomig
- DRUG AZD0901
- DRUG Trastuzumab Deruxtecan (T-DXd)
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Changchun
- Research Site - Changzhi
- Research Site - Chengdu
- Research Site - Chengdu
- Research Site - Fuzhou
- Research Site - Hangzhou
- Research Site - Hangzhou
- Research Site - Kunming
- Research Site - Qingdao
New York
- Research Site - New York
- Research Site - New York
Quebec
- Research Site - Montreal
- Research Site - Montreal
Delaware
- Research Site - Newark
District of Columbia
- Research Site - Washington D.C.
Kansas
- Research Site - Fairway
Michigan
- Research Site - North Shores
Pennsylvania
- Research Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-07-17 |
| Est. Completion | 2028-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07069712
The ClinicalTrials.gov registry entry for NCT07069712 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (28% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroesophageal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT07069712 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, New York, Quebec.
Frequently Asked Questions
What is clinical trial NCT07069712 about?
NCT07069712 is a clinical study titled "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma". GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcin...
What is the current status of trial NCT07069712?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-07-17. Estimated completion is 2028-09-06.
What conditions does trial NCT07069712 study?
This clinical trial studies the following conditions: Gastroesophageal Adenocarcinoma.
What interventions are being tested in trial NCT07069712?
The interventions under investigation include: Capecitabine (DRUG), 5-Fluorouracil (5-FU) (DRUG), Rilvegostomig (DRUG), AZD0901 (DRUG), Trastuzumab Deruxtecan (T-DXd) (DRUG).
Who is sponsoring clinical trial NCT07069712?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069712 being conducted?
This trial has 20 study locations across Delaware, District of Columbia, Kansas, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
-
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
ACTIVE NOT RECRUITING · Phase 2
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RECRUITING · Phase 1
-
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
RECRUITING · Phase 1
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.